LONGAVO
Live / Applied — Third extension granted (statement of use) (as of 16 Sept 2025)
What this means for you
Not registered yet, but its 14 Jun 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98041822
- Mark type
- Stylized text
- Filed
- 14 Jun 2023
- Published for opposition
- 06 Feb 2024
- Attorney of record
- Lori Wolfe
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for the treatment of neurological disorders
Owner
- TEVA PHARMACEUTICALS USA, Inc., Parsippany, NJ, US
- TEVA PHARMACEUTICALS USA, Inc., Parsippany, NJ, US
Prosecution history
- 18 Mar 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 18 Mar 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 18 Mar 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 17 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Sept 2025 — SOU EXTENSION 3 GRANTED
- 16 Sept 2025 — SOU EXTENSION 3 FILED
- 16 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 13 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Mar 2025 — SOU EXTENSION 2 GRANTED
- 12 Mar 2025 — SOU EXTENSION 2 FILED
- 12 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 25 Sept 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Sept 2024 — SOU EXTENSION 1 GRANTED
- 25 Sept 2024 — SOU EXTENSION 1 FILED
- 25 Sept 2024 — SOU TEAS EXTENSION RECEIVED